Merck's Colon Cancer Combination Therapy Fails to Meet Main Goal in a Phase 3 Study-March 2024-www.financetom.com

Merck's Colon Cancer Combination Therapy Fails to Meet Main Goal in a Phase 3 Study

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Merck's Colon Cancer Combination Therapy Fails to Meet Main Goal in a Phase 3 Study

Oct 3, 2024 1:16 AM

07:11 AM EDT, 09/25/2024 (MT Newswires) -- Merck ( MRK ) said on Wednesday that its experimental combination therapy for a type of previously treated metastatic colorectal cancer did not meet the primary goal of overall survival in a phase 3 study.

The drugmaker said that at the final pre-specified analysis, its fixed-dose combination of favezelimab and Keytruda did not improve overall survival compared to standard of care.

Merck ( MRK ) said it continues to evaluate the data and plans to share the findings with the scientific community.

Price: 115.19, Change: +0.23, Percent Change: +0.20

Previous page： Cummins Q3 Net Income, Revenue Increase; 2024 Revenue Outlook Maintained. Next page： Emerson Proposes Acquiring All Remaining Outstanding AspenTech Shares for $240 Each

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Cummins Q3 Net Income, Revenue Increase; 2024 Revenue Outlook Maintained.

Nov 5, 2024

08:05 AM EST, 11/05/2024 (MT Newswires) -- Cummins (CMI) reported Q3 net income Tuesday of $5.86 per diluted share, up from $4.59 a year earlier. Analysts polled by Capital IQ expected $4.84. Net sales for the quarter ended Sept. 30 was $8.46 billion, up from $8.43 billion a year earlier. Analysts surveyed by Capital IQ expected $8.31 billion. For 2024,...

Emerson Proposes Acquiring All Remaining Outstanding AspenTech Shares for $240 Each

Nov 5, 2024

07:50 AM EST, 11/05/2024 (MT Newswires) -- Emerson Electric ( EMR ) said Tuesday it has proposed acquiring all outstanding shares of AspenTech (AZPN) it does not already own for $240 each in cash. Upon deal completion, AspenTech would become a wholly owned subsidiary of Emerson, which currently owns roughly 57% of AspenTech's outstanding shares, Emerson said. Emerson also said...

Meta Platforms Reportedly Ordered to Pay $15.7 Million for Violating South Korea Privacy Rules

Nov 5, 2024

07:51 AM EST, 11/05/2024 (MT Newswires) -- Meta Platforms ( META ) has been ordered to pay 21.62 billion Korean won ($15.7 million) in fines by South Korea's privacy watchdog for collecting sensitive user data and handing it to advertisers, news outlets reported Tuesday. Meta's Facebook gleaned data on religion, sexuality, and politics from 980,000 South Korean users, which was...

TransAlta Swings To Q3 EPS GAAP Loss, But Says "Tracking Toward the Upper End of Its 2024 Guidance"

Nov 5, 2024

07:58 AM EST, 11/05/2024 (MT Newswires) -- TransAlta ( TAC ) on Tuesday reported a surprise EPS GAAP loss for the third quarter but said it is tracking toward the upper end of its 2024 guidance given its portfolio position and performance during the first nine months of the year. It reported net loss per share attributable to common shareholders,...